First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland

Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current oncology (Toronto) Jg. 32; H. 2; S. 64
Hauptverfasser: Peres, Tobias, Aeppli, Stefanie, Fischer, Stefanie, Hundsberger, Thomas, Rothermundt, Christian
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI 26.01.2025
MDPI AG
Schlagworte:
Adult
Aged
belzutifan
Carcinoma, Renal Cell - drug therapy
Case Report
case series
Female
haemangioblastomas
HIF-α inhibitor
Humans
Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors
Indenes
Kidney Neoplasms - drug therapy
Male
Middle Aged
renal cell carcinoma
Retrospective Studies
Switzerland
von Hippel-Lindau Disease - complications
von Hippel-Lindau Disease - drug therapy
von Hippel–Lindau syndrome
Switzerland
real-world
renal cell carcinoma
HIF-α inhibitor
belzutifan
case series
von Hippel–Lindau syndrome
haemangioblastomas
ISSN:1718-7729, 1198-0052, 1718-7729
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated in phase II and III studies, belzutifan is still not approved in many countries. In addition, von Hippel–Lindau syndrome is a rare disease. Therefore, there is virtually no real-world experience data of belzutifan efficacy available. We aim to determine the real-world efficacy and tolerability of belzutifan in patients with von Hippel–Lindau syndrome-associated tumours and in patients with sporadic advanced tyrosine kinase- and immune checkpoint inhibitors pre-treated for renal cell carcinoma. A retrospective analysis of five patients treated with belzutifan between 2023 and 2024 at a Swiss cancer centre was conducted. In this case series, all patients consistently benefitted from belzutifan with response to treatment. This case series provides real-world evidence that belzutifan is an effective and well-tolerated treatment option for patients with von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and sporadic advanced pre-treated renal cell carcinoma.
Bibliographie:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol32020064